WASHINGTON, May 12 — The FDA is investigating a possible link to heparin in the deaths of two Delaware residents who suffered cerebral hemorrhages following heparin treatment.

The deaths of a 71-year-old man and a 64-year-old woman occurred over the weekend. A third patient, a 68-year-old man, remains hospitalized. All three became ill after taking heparin last week, according to officials at Beebe Medical Center in Lewes, Delaware.

The Associated Press reported that the 71-year-old man died after being transferred to Christiana Hospital in Newark, Delaware, while the woman was transferred to the University of Maryland hospital in Baltimore, where she died.

The third patient remains hospitalized at Christiana Hospital. All three suffered cerebral hemorrhages.

Beebe Medical Center said the patients were treated with heparin supplied by Baxter International.

Baxter, which is the largest supplier of heparin in the U.S., was at the center of the worldwide heparin contamination, which caused hundreds of allergic reactions and a number of deaths in 2008.

In that investigation, the FDA traced the problem to oversulfated chondroitin sulfate in raw material from China.

Baxter said the heparin given the Delaware patients was made from raw material supplied by Pfizer, which gets its active pharmaceutical ingredients from a supplier in Ohio.

The Beebe Medical Center informed Baxter on Friday that three patients had become ill, and the company informed the FDA.

Both Baxter and the FDA have sent teams to Delaware to investigate the cases.

Related Article(s):

• Contaminated Heparin Confirmed as Cause of Allergic Reactions